Bulletin
Investor Alert

Topics

Hepatitis

7:04 a.m. Oct. 4, 2020 - By Jaimy Lee
Abbott exec: Why better COVID-19 tests may help the U.S. get back to normal John Hackett is a longtime executive at diagnostics company Abbott In less than seven months, Abbott Laboratories has introduced six COVID-19 tests, each a little different than the last, and that’s all part of the diagnostics company’s strategy to keep improving and enhancing tests that can detect current and past infections with the novel coronavirus.
11:23 a.m. Sept. 6, 2020 - By Quentin Fottrell
Sweden embraced herd immunity, while the U.K. abandoned the idea — so why do they both have high COVID-19 fatality rates? ‘Sweden’s prized herd immunity is nowhere in sight,’ according to an analysis in the Journal of the Royal Society of Medicine‘Sweden’s prized herd immunity is nowhere in sight,’ according to an analysis in the Journal of the Royal Society of Medicine.
12:58 a.m. Aug. 10, 2020 - By Sherri Snelling
Could flu vaccines lower your risk of Alzheimer’s? Research sheds new light Two studies released at the Alzheimer’s Association conference indicate a possible connection between flu and pneumonia shots with reducing or delaying cognitive declineThe studies show ‘vaccines are strongly associated with lower prevalence of dementia,’ says one scientist.
2:13 a.m. July 31, 2020 - By Jaimy Lee
Gilead swings to a big loss on acquisition expense, stock falls after earnings and revenue miss The drugmaker expects to produce more than 2 million courses of COVID-19 treatment remdesivir by the end of the yearShares of Gilead Sciences Inc. fell more than 1% in after-hours trading Thursday after the drugmaker reported that it swung to a large loss during the second quarter and missed estimates even after adjusting for an acquisition.
2:11 a.m. June 30, 2020 - By Jaimy Lee
Gilead’s coronavirus drug will cost $2,340 — which sounds expensive, but here’s why it’s not The drugmaker’s decision to price remdesivir below expectations could be a ‘promising sign’ of how much other COVID-19 treatments will cost, said one expertGilead Sciences Inc.’s COVID-19 drug remdesivir will cost much less than Wall Street analysts had predicted in a move that likely points to a more measured, responsible approach to the pharmaceutical pricing of treatments and vaccines during the pandemic.
10:06 a.m. June 29, 2020 - By Jaimy Lee
Race for a COVID-19 vaccine has drug makers scaling up manufacturing — before one is developed ‘People, companies are starting to plan to make doses even before, you know, the vaccine works,’ Dr. Anthony Fauci said Tuesday on Capitol HillInovio Pharmaceuticals Inc. has yet to share results from the Phase 1 trial for its COVID-19 vaccine candidate, but has already received millions of dollars in funding to scale up manufacturing capacity.
9:34 a.m. May 31, 2020 - By Quentin Fottrell
‘The 1918 Spanish flu’s second wave was even more devastating’: WHO advises caution to avoid ‘immediate second peak’ Immunizations against smallpox, measles or Hepatitis B should last a lifetime, but that has not been the case for previous coronavirusesImmunizations against smallpox, measles or Hepatitis B should last a lifetime, but that has not been the case for previous coronaviruses.
Browse topics:
Link to MarketWatch's Slice.